Alliance for Clinical Trials in Oncology
@ALLIANCE_org
Utilizing the best science to develop promising new cancer therapies and prevention strategies for cancer.
At least 40% of #cancers are linked to things we can change or manage, such as: - Avoiding tobacco - Protecting your skin - Limiting alcohol - Keeping a healthy weight - Getting tested for hepatitis C Learn how to lower your risk: bit.ly/3VbeyQk
The #ERASur trial is enrolling patients w/#colorectalcancer that has spread beyond the liver. Patients who responded well to initial chemo & have up to 4 treatable cancer sites be eligible to participate. Learn more: bit.ly/Alliance-A0221… @FightCRC @CCAlliance @COLONTOWN
#DYK #ERASur led by @EricMillerMDPhD @OSUCCC_James is testing whether adding targeted treatments like surgery, radiation or heat therapy to standard chemo can help people w/metastatic #colorectalcancer live longer: bit.ly/Alliance-A0221… @FightCRC @ColorectalCAN @ColonCancerCoal
#ICYMI .@thomashopemd @UCSF .@SukiPaddaMD @CedarsSinai lead @ALLIANCE_org A021901/B-LuRE that studies the effect of everolimus vs 177Lu-dotatate in patients w/bronchial #neuroendocrine tumors. Learn more bit.ly/Alliance-A0219… #bronchialcancer #NCI #NCTN #NETs @eaonc @FightCRC
Testing for certain features in cancer (biomarkers) can tell doctors about what’s causing it to grow. The #myeloMATCH study uses advanced biomarker testing for adults with #AML or #MDS. 1-800-4-CANCER or swog.org/myeloMATCH @theNCI @ALLIANCE_org @CDNCancerTrials @eaonc…
Standard chemo is the norm for metastatic #colorectalcancer — but can more be done? The #ERASur trial is exploring whether adding radiation, heat therapy or surgery can extend life. Learn more: bit.ly/Alliance-A0221… @ColonCancerCoal @FightCRC @ColorectalCAN #TrialTuesday #NCI
For #TrialTuesday, @ArdamanShergil1 @UCCancerCenter leads #ComboMATCH Treatment Trial A6 to compare chemo w/wo binimetinib to shrink tumors in patients with advanced biliary tract cancers in a 2nd line setting. Learn more: bit.ly/cmatch-A6 #PrecisionMedicine @ALLIANCE_org
Congratulations to UNC Lineberger’s @EthanBasch1, MD, MSc, FASCO and the e-PRO initiative on receiving the Clinical Innovation Award from @GoHealio and City of Hope! This honor recognizes groundbreaking work to improve patient care through electronic patient-reported outcomes.…
Now Available @MMCORC locations >>> the @ALLIANCE_org A012301 (LoTam) study to compare the effect of low dose tamoxifen to usual hormonal therapy in treating post-menopausal women w/hormone positive HER2- early-stage bit.ly/Alliance-A0123…… #NCI #NCTN #BCsm
Kudos to @ALLIANCE_org Breast Committee Co-Chairs - Jennifer Ligibel, MD and @AnnPartridgeMD!
With Dr. Jennifer Ligibel and @AnnPartridgeMD at #ASCO25 — extraordinary mentors and scientists. Their guidance, and that of several other inspiring women at @DFCI_BreastOnc, continues to shape my journey and the research we’re building together!
Hats to @BiostatGirl on your presentation at #ASCO25 on the patient-reported outcomes results from the @ALLIANCE_org A021602/CABINET trial.
PROs in the CABINET trial presented by me - cabozantinib for previously-treated advanced neuroendocrine tumors. Side effects & function declined, but HRQOL & overall status improved. Excited for more analysis! #ASCO25 @ALLIANCE_org
First up at #ASCO25 Plenary: According to ATOMIC results, adding atezo to FOLFOX improves DFS in stage III dMMR #ColonCancer & yields 50% reduction in the risk of recurrence & death vs chemo alone: brnw.ch/21wT4N9 #ASCODailyNews @FASinicropeMD @mayoclinic @MyriamChalabi
CTx vs CTx + atezolizumab as adj. therapy for stage III deficient DNA MSI/ dMMR mCRC 🔥#ASCO25 Plenary session🔥 🔎Alliance A021502; ATOMIC 👉mDFS 86.4 vs 76. 6, HR 0.5 👉Benefit in all subgroups, OS not yet mature 👉Manageable safety profile 🧐 Practice changing, new SOC…
Congrats to the ATOMIC/A021502 investigators ! @ALLIANCE_org positive DFS and OS for adjuvant dMMr CRC. Years of work and hundreds of patients. @NCICancerTrials @ASCO
1st Plenary #ASCO25: #ATOMIC Ph III, adj mFOLFOX + Atezolizumab vs. mFOLFOX in Stg III dMMR colon ca. - 3yr DFS 86.4% vs 76.6% (HR 0.50), benefit seen in all subgroups. DFS 100% in Niche2 - ⬆️ discontinuation w/ Atezo - OS not mature - ⬆️ Gr4 neutropenia - To Adj or to NeoAdj?
Kudos to @FASinicropeMD, the study team, enrolling sites/institutions, clinical research specialists/staff, partners/collaborators & most of all - study participants on the results of A021502/ATOMIC - a study for pts with dMMR colon cancer! Learn more: bit.ly/ATOMIC-ASCO
Cancer survivorship isn’t just about living — it’s about thriving. On #NationalCancerSurvivorsDay, we #CelebrateLife and honor the strength of survivors everywhere. Let's also champion the power of #cancerresearch to make survivorship not only possible, but fuller. #NCSD2025
We enrolled #PDIGREE over 5 yrs including a pandemic, and in that time, 7 phase 3 trials read out that shaped the metastatic #kidneycancer landscape. Grateful for support throughout @ALLIANCE_org @theNCI to complete this smart/fortunate trial design. #ASCO25 @OncoAlert 6/n
Join Dr. Ashley Odai-Afotey (@AshleyOdai) at the #ASCO25 Care Delivery/Models of Care poster session on Sunday and learn how race and ethnicity impacted intervention adherence, engagement, and tool utilization in the #BreastCancer weight loss (#BWEL) trial (@ALLIANCE_org…
After many years of hard work starting in 2014, we present Step 1 of #PDIGREE presented by @TiansterZhang in advanced RCC ! 1100 patients and 400+ sites ! #ASCO25 @ASCO @ALLIANCE_org